Chemomab Therapeutics Ltd. (CMMB)
$1.29+4.03%Close
SELLCRISIS · day 17
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8M
- Beta
- 0.66
- P/E (TTM)
- -1.26
- Short % float
- 0.19%
- Days to cover
- 1.0
- SI change
- -87.1%
- 1W
- -5.84%
- 1M
- -47.77%
- vs SPY 1W
- -5.70%
- vs SPY 1M
- -50.28%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 8
- VALUE
- 18
- GROWTH
- 39
- GARP
- 0
- TYPE
- Value / Recovery (blended)
Composite of Value · Growth · GARP
ROIC-42.5%
REV YoY-
ROE-70.8%
EPS YoY-
ROA-74.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.26
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.19
P/FCF-
EV/EBITDA-0.25
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO6.41
ND/EBITDA-
BETA0.66
Company news
FAQ
- What is LOPJLB’s current signal on CMMB?
- LOPJLB’s latest quantitative signal on Chemomab Therapeutics Ltd. (CMMB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is CMMB in?
- Chemomab Therapeutics Ltd. (CMMB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Chemomab Therapeutics Ltd. (CMMB) do?
- Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for…